| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | Chief Financial Officer | Common Stock | 118,363 | $156,239 | $1.32 | 20 Feb 2026 | Direct |
| AN2 Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 77,000 | 20 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | 20 Feb 2026 | 2 | $0 | 4 | Chief Financial Officer | 23 Feb 2026, 16:40 |
| ANTX | AN2 Therapeutics, Inc. | 05 Jan 2026 | 2 | -$8,883 | 4 | Chief Financial Officer | 07 Jan 2026, 20:15 |
| ANTX | AN2 Therapeutics, Inc. | 26 Feb 2025 | 2 | $0 | 4 | Chief Financial Officer | 28 Feb 2025, 16:26 |
| ANTX | AN2 Therapeutics, Inc. | 03 Jan 2025 | 1 | -$3,965 | 4 | Chief Financial Officer | 07 Jan 2025, 20:02 |
| ANTX | AN2 Therapeutics, Inc. | 15 Mar 2024 | 1 | $0 | 4/A | Chief Financial Officer | 29 Mar 2024, 16:18 |
| ANTX | AN2 Therapeutics, Inc. | 15 Mar 2024 | 2 | $0 | 4 | Chief Financial Officer | 18 Mar 2024, 19:29 |
| ANTX | AN2 Therapeutics, Inc. | 15 Feb 2023 | 1 | $0 | 4 | Chief Financial Officer | 17 Feb 2023, 18:29 |
| ANTX | AN2 Therapeutics, Inc. | 12 May 2022 | 1 | $0 | 4 | Chief Financial Officer | 16 May 2022, 21:15 |
| ANTX | AN2 Therapeutics, Inc. | 24 Mar 2022 | 0 | $0 | 3 | Chief Financial Officer | 24 Mar 2022, 21:19 |